Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 50 to 59 years~* Determined by medical history, physical examination and clinical judgement to be eligible for the study~* Able to complete electronic diary~* Available for the 5 year 9 month duration of the study~Exclusion Criteria:~* Previous vaccination with any licensed or experimental pneumococcal vaccine~* Allergic to egg proteins and chicken proteins~* History of Guillian-Barre syndrome~* Vaccination with TIV within 6 months before study start~* Vaccination with diphtheria-containing vaccine within 6 months of study start~* Serious chronic disorders including immunodeficiency or metastatic malignancy~* Known or suspected hypersensitivity to any vaccine or vaccine component

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 59 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: OTHER): arm 1 = TIV +13vPnC at visit 1, placebo at visit 2 then 13vPnC at year 5
- 2 (Type: OTHER): arm 2 = TIV + placebo at visit 1, then 13vPnC at visit 2 and at year 5

Based on this trial design, predict the completion outcome and termination type (if applicable).